|Bid||2.1100 x 800|
|Ask||2.1600 x 21500|
|Day's Range||2.0500 - 2.1900|
|52 Week Range||1.5600 - 4.1400|
|Beta (3Y Monthly)||0.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.79|
Moody's Investors Service ("Moody's") today upgraded the Corporate Family Rating (CFR) of BioScrip, Inc. ("BioScrip") to B3 from Caa1 and upgraded the Probability of Default to B3-PD from Caa1-PD. At the same time, Moody's upgraded the Speculative Grade Liquidity Rating to SGL-3 from SGL-4 and assigned a B2 (LGD 3) rating to the proposed $925 million First Lien Term Loan B. The outlook is stable. The upgrade reflects the improvement in BioScrip's credit profile due to the pending merger with HC Group Holdings III, Inc. (dba Option Care).
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the fourth quarter, which unveil their equity positions as of December 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
NEWTOWN SQUARE, Pa., May 03, 2019 -- Kaskela Law LLC announces that it is investigating BioScrip, Inc. (“BioScrip” or the “Company”) (Nasdaq: BIOS) on behalf of the Company’s.
BioScrip (BIOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioScrip (BIOS) delivered earnings and revenue surprises of 16.67% and 0.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Denver-based company said it had a loss of 10 cents. The infusion and home care services company posted revenue of $179 million in the period. The company's shares closed at $1.90. ...
DENVER, May 02, 2019 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions,.
BioScrip, Inc. (BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today provided an update on its proposed merger with Option Care Enterprises, Inc. (“Option Care”). The Company expects to file the preliminary Option Care merger proxy statement the week of April 29, 2019 with the U.S. Securities and Exchange Commission (“SEC”). After the proxy statement is filed, management from both BioScrip and Option Care plan to conduct joint analyst and investor meetings. As part of the analyst and investor meetings, the Company will file an investor presentation with the SEC that will include a business and merger update.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of HC Group Holdings III, Inc. New York, April 18, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of HC Group Holdings III, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
BioScrip, Inc. (BIOS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
BioScrip (BIOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Q4 2018 BioScrip Inc Earnings and Definitive Merger Agreement with Option Care Call
Moody's Investors Service ("Moody's") today placed the ratings of BioScrip, Inc. (BioScrip), including the Caa1 Corporate Family Rating (CFR), under review for upgrade. This follows the announcement that BioScrip will merge with HC Group Holdings III, Inc.(dba Option Care). BioScrip will issue common stock to Option Care in an all-stock deal.
Shares of BioScrip Inc. tumbled 9.0% toward a 9-month low in midday trade Monday, extending the sharp reversal suffered early in the previous session as investors digested the terms of the company's merger deal with Option Care Enterprises Inc. On Friday, the stock soared as much as 71% in premarket trade, and as much as 8.0% during the regular session, before pulling a sharp U-turn to close down 20.3%. Canaccord Genuity analyst Richard Close said that investors may have to suffer some short-term pain, given the disappointment that BioScrip shareholders will own just 20% of the post-merger company, but he remains bullish given the long-term potential. "The need for scale in health care is increasingly paramount as the provider and payer markets consolidate and reimbursement risk is always present," Close wrote in a research note. "Thus, having scale is a significant advantage as [BioScrip] seeks to negotiate rates and drive sustained operating results." The stock has tumbled 35.5% year to date, while the S&P 500 has climbed 12.7%.
Investors need to pay close attention to BioScrip (BIOS) stock based on the movements in the options market lately.
NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity researchand corporate access firm focused on small and mid-cap public companies isissuing a comprehensive report on BioScrip Inc. (BIOS), a provider of infusion and home care management solutions, with approximately 2,500 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. Recently, BioScrip and Option Care jointly announced a definitive merger agreement, which will create the nation's preeminent home infusion company and transform the industry. Option Care's signature Home Infusion Plus services include the clinical management of infusion medicines, nursing support, and care coordination.
agreed to buy rival Option Care Enterprises, creating one of the largest independent home-therapy companies in the U.S. On completion of the all-stock deal, MDP funds and WBA will own roughly 80% of the combined publicly traded company on a fully diluted basis, with current BioScrip shareholders holding the remainder, the companies said. Option Care CEO John Rademacher will lead the combined company.
Shares of BioScrip Inc. soared 32% toward a 4-year high in premarket trade Friday, after the company announced a deal to merge with privately held Option Care Enterprises Inc., a provider of home and alternate treatment site infusion therapy services owned by funds affiliated with Walgreens Boots Alliance Inc. and private-equity firm Madison Dearborn Partners LLC (MDP). BioScrip's stock is halted for news until 7:30 a.m. Eastern. Under terms of the agreement, BioScrip will issue new shares to Option Care's shareholder and Walgreens and MDP will own about 80% of the combined publicly traded company. BioScrip's market capitalization was about $446.9 million as of Thursday's close. "This is a compelling and complementary fit of two leading players in the U.S. infusion market," said BioScrip Chief Executive Daniel Greenleaf. "Together, we will be able to provide a diverse set of life-improving and cost-effective services to more patients across the United States." BioScrip's stock has rallied 31% over the past 12 months, while the SPDR Health Care Select Sector ETF has gained 6.9% and the Dow Jones Industrial Average has tacked on 3.4%.